These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Cryz SJ; Fürer E; Que JU Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901 [TBL] [Abstract][Full Text] [Related]
10. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Cryz SJ; Fürer E; Germanier R Infect Immun; 1984 Mar; 43(3):795-9. PubMed ID: 6698608 [TBL] [Abstract][Full Text] [Related]
11. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Boutonnier A; Villeneuve S; Nato F; Dassy B; Fournier JM Infect Immun; 2001 May; 69(5):3488-93. PubMed ID: 11292781 [TBL] [Abstract][Full Text] [Related]
12. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. Matthews-Greer JM; Gilleland HE J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. Wessels MR; Paoletti LC; Pinel J; Kasper DL J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814 [TBL] [Abstract][Full Text] [Related]
14. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346 [TBL] [Abstract][Full Text] [Related]
15. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans. Cryz SJ; Sadoff JC; Fürer E Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides. Schreiber JR; Dahlhauser P Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Cryz SJ; Sadoff JC; Ohman D; Fürer E J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471 [TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577 [TBL] [Abstract][Full Text] [Related]
19. Conjugate vaccines against Pseudomonas aeruginosa and malaria. Cryz SJ; Sadoff JC; Que JU Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972 [No Abstract] [Full Text] [Related]
20. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]